A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-0539 ◽

2021 ◽

pp. clincanres.0539.2021

Author(s):

Gang An ◽

Daobin Zhou ◽

Shu Cheng ◽

Ke-Shu Zhou ◽

Jianyong Li ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Phase Ii ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Waldenström Macroglobulinemia ◽

Waldenstrom Macroglobulinemia ◽

Bruton Tyrosine Kinase

Download Full-text

Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenström macroglobulinemia

The Lancet Haematology ◽

10.1016/s2352-3026(19)30214-5 ◽

2020 ◽

Vol 7 (2) ◽

pp. e85-e86

Author(s):

Christian Buske

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Waldenström Macroglobulinemia ◽

Waldenstrom Macroglobulinemia ◽

Bruton Tyrosine Kinase

Download Full-text

Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-11-0048 ◽

2011 ◽

Vol 10 (6) ◽

pp. 1102-1112 ◽

Cited By ~ 113

Author(s):

Monika E. Hegi ◽

Annie-Claire Diserens ◽

Pierre Bady ◽

Yuta Kamoshima ◽

Mathilde C. M. Kouwenhoven ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Phase Ii ◽

Pathway Analysis ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Preoperative Treatment ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’

European Journal of Cancer ◽

10.1016/j.ejca.2020.04.021 ◽

2020 ◽

Vol 134 ◽

pp. 62-74 ◽

Cited By ~ 5

Author(s):

Patrick Schöffski ◽

Olivier Mir ◽

Bernd Kasper ◽

Zsuzsanna Papai ◽

Jean-Yves Blay ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Phase Ii ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Gastrointestinal Stromal Tumour ◽

Stromal Tumour ◽

European Organisation

Download Full-text

Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor

Haematologica ◽

10.3324/haematol.2015.132845 ◽

2015 ◽

Vol 100 (12) ◽

pp. e494-e495 ◽

Cited By ~ 7

Author(s):

D. Sanford ◽

H. Kantarjian ◽

J. Skinner ◽

E. Jabbour ◽

J. Cortes

Keyword(s):

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Phase Ii ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Phase Ii Trial

Download Full-text

A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy

Annals of Oncology ◽

10.1093/annonc/mds003 ◽

2012 ◽

Vol 23 (9) ◽

pp. 2265-2271 ◽

Cited By ~ 48

Author(s):

K.H. Baumann ◽

A. du Bois ◽

W. Meier ◽

J. Rau ◽

P. Wimberger ◽

...

Keyword(s):

Ovarian Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Phase Ii ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Multicenter Trial ◽

Dosage Schedule ◽

Receptor Tyrosine Kinase Inhibitor

Download Full-text

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Annals of Oncology ◽

10.1093/annonc/mdv186 ◽

2015 ◽

Vol 26 (7) ◽

pp. 1421-1427 ◽

Cited By ~ 132

Author(s):

M.G. Kris ◽

D.R. Camidge ◽

G. Giaccone ◽

T. Hida ◽

B.T. Li ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Phase Ii ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Lung Cancers

Download Full-text

Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

Neuro-Oncology ◽

10.1093/neuonc/nox105 ◽

2017 ◽

Vol 19 (11) ◽

pp. 1522-1531 ◽

Cited By ~ 37

Author(s):

Juan Manuel Sepúlveda-Sánchez ◽

María Ángeles Vaz ◽

Carmen Balañá ◽

Miguel Gil-Gil ◽

Gaspar Reynés ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Phase Ii ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Recurrent Glioblastoma ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Amplification ◽

Egfr Tyrosine Kinase

Download Full-text

B526 PKC412, Small-Molecule Tyrosine Kinase Inhibitor, Regulates Survival in Waldenström Macroglobulinemia

Clinical Lymphoma & Myeloma ◽

10.1016/s1557-9190(11)70758-2 ◽

2009 ◽

Vol 9 ◽

pp. S144

Author(s):

MR Melhem ◽

AM Roccaro ◽

AK Azab ◽

HT Ngo ◽

A Sacco ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Small Molecule ◽

Kinase Inhibitor ◽

Waldenström Macroglobulinemia ◽

Waldenstrom Macroglobulinemia

Download Full-text

Faculty Opinions recommendation of A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725749411.793548434 ◽

2018 ◽

Author(s):

Camilo Jimenez

Keyword(s):

Thyroid Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Phase Ii ◽

Medullary Thyroid Cancer ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Medullary Thyroid ◽

Multitargeted Tyrosine Kinase Inhibitor

Download Full-text

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-15-1127 ◽

2015 ◽

Vol 22 (1) ◽

pp. 44-53 ◽

Cited By ~ 110

Author(s):

Martin Schlumberger ◽

Barbara Jarzab ◽

Maria E. Cabanillas ◽

Bruce Robinson ◽

Furio Pacini ◽

...

Keyword(s):

Thyroid Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Phase Ii ◽

Medullary Thyroid Cancer ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Medullary Thyroid ◽

Multitargeted Tyrosine Kinase Inhibitor

Download Full-text